FY2025 EPS Estimates for TSE:ONC Increased by HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Equities researchers at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research report issued on Monday, November 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.35) per share for the year, up from their prior forecast of ($0.39). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.32) EPS, FY2028 earnings at ($0.31) EPS and FY2029 earnings at ($0.05) EPS.

Oncolytics Biotech (TSE:ONC) last posted its earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter.

Separately, Lake Street Capital upgraded shares of Oncolytics Biotech to a “strong-buy” rating in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy”.

Oncolytics Biotech Stock Performance

ONC stock opened at C$14.90 on Wednesday. Oncolytics Biotech has a one year low of C$0.44 and a one year high of C$2.08. The firm has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The firm has a 50-day simple moving average of C$14.90 and a two-hundred day simple moving average of C$7.01.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.